SPRUCE BIOSCIENCES, INC.
SPRUCE BIOSCIENCES, INC. (SPRB): 6 pipeline candidates · 3 upcoming catalysts · ~14 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.6 months
D/E 0.62 · 0% dilution
Lead: Phase 3
6 candidates
3 upcoming, next in ~12d
N/A
A transparent, data-derived signal for SPRUCE BIOSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$134.2M
Cash
$54.1M
Quarterly Burn
$12.0M
Runway
13.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| spr001 | Phase 2 |
| spr202 | Preclinical |
| spr204 | Preclinical |
| ta-ert | Phase 3 |
| tildacerfont | Phase 2 |
| tralesinidase alfa | Phase 3 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
30
Total value held
$38.3M
| Holder | Shares | Value |
|---|---|---|
| millennium management llc | 111,888 | $7.3M |
| citadel advisors llc | 69,999 | $4.6M |
| adar1 capital management, llc | 58,600 | $3.8M |
| alyeska investment group, l.p. | 51,671 | $3.4M |
| wellington management group llp | 48,796 | $3.2M |
| boothbay fund management, llc | 42,080 | $2.7M |
| balyasny asset management l.p. | 40,000 | $2.6M |
| quinn opportunity partners llc | 26,810 | $1.8M |
| exoduspoint capital management, lp | 22,000 | $1.4M |
| vanguard capital management llc | 18,337 | $1.2M |
Showing top 10 of 30 institutional holders of SPRUCE BIOSCIENCES, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SPRUCE BIOSCIENCES, INC.'s pipeline?
SPRUCE BIOSCIENCES, INC. (SPRB) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SPRUCE BIOSCIENCES, INC.'s lead drug candidate?
SPRUCE BIOSCIENCES, INC.'s most advanced tracked candidate is spr001 (Phase 2) for Congenital Adrenal Hyperplasia.
What is SPRUCE BIOSCIENCES, INC.'s next catalyst?
SPRUCE BIOSCIENCES, INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: Major Depressive Disorder" — expected June 30, 2026.
What is SPRUCE BIOSCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SPRUCE BIOSCIENCES, INC. has approximately 13.6 months of cash runway.
What is SPRUCE BIOSCIENCES, INC.'s market capitalization?
SPRUCE BIOSCIENCES, INC.'s market capitalization is approximately $134.2M.
Get the full picture on SPRUCE BIOSCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.